- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| TURNSTONE BIOLOGICS Aktie jetzt für 0€ handeln | |||||
| 27.06. | Turnstone Biologics Corp. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.06. | Turnstone, once allied with AbbVie and Takeda, accepts $8M Xoma buyout | 11 | FierceBiotech | ||
| 27.06. | XOMA-Aktie steigt nach Übernahme von Turnstone Biologics | 1 | Investing.com Deutsch | ||
| 27.06. | XOMA stock rises after acquisition of Turnstone Biologics | 1 | Investing.com | ||
| 27.06. | Turnstone Biologics to be acquired by XOMA Royalty | 3 | Seeking Alpha | ||
| 27.06. | XOMA Royalty to acquire Turnstone Biologics for $0.34 per share | 2 | Investing.com | ||
| 27.06. | Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right | 198 | GlobeNewswire (Europe) | EMERYVILLE, Calif. and SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (Nasdaq: XOMA) and Turnstone Biologics Corp. ("Turnstone" or the "Company") (Nasdaq-CM:... ► Artikel lesen | |
| 09.05. | Turnstone Biologics GAAP EPS of -$0.51 | 2 | Seeking Alpha | ||
| 09.05. | Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights | 85 | GlobeNewswire (Europe) | SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (Nasdaq-CM: TSBX), a biotechnology company historically focused on the development of a differentiated... ► Artikel lesen | |
| 31.03. | Turnstone Biologics GAAP EPS of -$0.56 misses by $0.36 | 2 | Seeking Alpha | ||
| 29.03. | Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results | 422 | GlobeNewswire (Europe) | SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (Nasdaq: TSBX), a biotechnology company historically focused on the development of a differentiated... ► Artikel lesen | |
| 05.02. | Piper Sandler cuts Turnstone Biologics stock rating to neutral | 1 | Investing.com | ||
| 04.02. | Turnstone ends last remaining clinical program due to costs, plots more layoffs | 1 | FierceBiotech | ||
| 04.02. | Turnstone Biologics stoppt TIDAL-01-Entwicklung und sucht nach Alternativen | 1 | Investing.com Deutsch | ||
| 04.02. | Turnstone Biologics halts TIDAL-01 development, seeks alternatives | 4 | Investing.com | ||
| 04.02. | Turnstone Biologics Corp.: Turnstone Biologics Announces Plans to Explore Strategic Alternatives | 172 | GlobeNewswire (Europe) | SAN DIEGO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (Nasdaq: TSBX) today announced that it has completed an assessment of its business and operations... ► Artikel lesen | |
| 04.02. | Turnstone Biologics Corp. - 8-K, Current Report | - | SEC Filings | ||
| 11.10.24 | Turnstone Biologics Corp.: Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway | 875 | GlobeNewswire (Europe) | Realigning resources to focus on clinical advancement of Selected TIL therapyReducing employee headcount by approximately 60%Streamlining operations with cash runway expected to extend into 2Q 2026... ► Artikel lesen | |
| 14.08.24 | Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights | 240 | GlobeNewswire (Europe) | Announced positive initial data from Phase 1 trial of TIDAL-01 in metastatic colorectal cancer including a complete response in one of the four patients reported Cash position expected to fund operations... ► Artikel lesen | |
| 14.08.24 | Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer | 227 | GlobeNewswire (Europe) | Overall response rate ("ORR") of 25% and 50% disease control rate ("DCR") observed in first four evaluable patients treated with TIDAL-01 with advanced CRC Complete response achieved in heavily pre-treated... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 0,245 | +12,90 % | Palatin Technologies, Inc.: Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity | Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatment
Combination of oral PL7737 and tirzepatide resulted in additive... ► Artikel lesen | |
| BIOXXMED | 0,320 | -21,95 % | EQS-News: bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024 | EQS-News: bioXXmed AG
/ Schlagwort(e): Jahresbericht
bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024
27.06.2025 /... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
| OCUGEN | 0,902 | +0,96 % | Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST-Novel Modifier Gene Therapy Candidate for Stargardt Disease | MALVERN, Pa., July 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
| BIO-GATE | 1,000 | -3,85 % | Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts | Nürnberg (www.anleihencheck.de) - Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts - AnleihenewsVorstand und Aufsichtsrat der Bio-Gate AG (ISIN DE000BGAG981/... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,370 | -1,07 % | Defence Therapeutics Inc.: Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer | Montreal, Quebec--(Newsfile Corp. - July 14, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
| VAXART | 0,320 | 0,00 % | Vaxart, Inc.: Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq | - Special Meeting of Stockholders to be Held Virtually on September 5, 2025 - - Live Stockholder Fireside Chat to be Scheduled to Answer Frequently Asked Stockholder Questions - - Nasdaq Hearings... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 1,550 | -7,74 % | Burcon NutraScience Corporation: Burcon to Showcase Chipotle Black Bean Protein Hummus at 2025 IFT FIRST Annual Event & Expo | Vancouver, British Columbia--(Newsfile Corp. - July 10, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 5,030 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement | Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for Triple-Negative... ► Artikel lesen | |
| AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic ... | OCALA, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today reported positive data in a mid-year update from the ongoing Phase 2 clinical... ► Artikel lesen | |
| IMMUNIC | 0,934 | -0,21 % | EQS-News: Immunic AG: Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis | Issuer: Immunic AG
/ Key word(s): Study/Study results
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,050 | -9,06 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
| CEL-SCI | 8,760 | 0,00 % | CEL-SCI Corporation: CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer | Strong interest from Saudi investment funds in CEL-SCI, Multikine, and potential joint venture to address the wider Middle East and North Africa market Patient access and reimbursement/sale in... ► Artikel lesen |
Das Unternehmen TURNSTONE BIOLOGICS CORP kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,94 % bei einem Aktienkurs von 0,353 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TURNSTONE BIOLOGICS CORP finden Sie auf Wallstreet Online.